e94b6daf-3aed-4496-b64b-1b1a7d8e2011
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 45
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.520
- OXIDATIVE_PHOSPHORYLATION+0.510
- P53_PATHWAY+0.450
- FATTY_ACID_METABOLISM+0.410
- PROTEIN_SECRETION+0.390
- MTORC1_SIGNALING+0.380
- PEROXISOME+0.370
- ADIPOGENESIS+0.290
- ESTROGEN_RESPONSE_LATE+0.290
- GLYCOLYSIS+0.290
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- G2M_CHECKPOINT-0.390
- WNT_BETA_CATENIN_SIGNALING-0.350
- E2F_TARGETS-0.330
- ALLOGRAFT_REJECTION-0.320
- IL6_JAK_STAT3_SIGNALING-0.240
- INFLAMMATORY_RESPONSE-0.210
- NOTCH_SIGNALING-0.200
- HEDGEHOG_SIGNALING-0.190
- SPERMATOGENESIS-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A07P-01A-11R-A00Z-07 | — | B | 0.801 |
| 2 | TCGA-IQ-7632-01A-11R-2081-07 | — | — | 0.797 |
| 3 | ee24b470-4509-4687-a91e-6d2b967336b9 | — | — | 0.786 |
| 4 | SRR8943024 | — | — | 0.782 |
| 5 | bf93be3e-d4f1-4efb-9841-ca8ad81b237e | — | — | 0.781 |
| 6 | SRR4296070 | — | cohortA1 | 0.773 |
| 7 | TCGA-B6-A0RO-01A-22R-A084-07 | — | C | 0.771 |
| 8 | SRR8518413 | — | F | 0.770 |
| 9 | AUR-AD9F-TTM3-A-1-1-R-A542-39 | — | C | 0.769 |
| 10 | AUR-AD9I-TTM3-A-1-1-R-A542-39 | — | C | 0.767 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.520 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.510 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.450 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.410 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.380 | Inavolisib | — uncovered |
| PEROXISOME | 0.370 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.290 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.290 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.290 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.270 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.240 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| HYPOXIA | 0.140 | Idelalisib | — uncovered |
| APOPTOSIS | 0.130 | Idelalisib | — uncovered |